Merck (NYSE: MRK) has revealed positive data from the Phase III KEYNOTE-426 trial of Keytruda (pembrolizumab) plus Inlyta (axitinib) in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC).
The combination of Keytruda and Pfizer’s (NYSE: PFE) tyrosine kinase inhibitor met both primary endpoints of overall survival (OS) and progression-free survival (PFS), based on the first interim analysis.
The trial compared the combo with Sutent (sunitinib) monotherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze